As major pharmaceutical companies’ patent monopolies over lucrative drugs wind down toward expiration, the legal maneuvering to keep generic competitors out of the market heats up.
As a patent is about to expire, generics makers can seek streamlined FDA approval if their drug is a bioequivalent of the patented version. One controversial means of delaying low-priced generics entering the market in recent years has been use of the regulatory process known as “citizen petitions” brought before the Food and Drug Administration, which temporarily halts generic approvals while the FDA investigates safety challenges raised in the petitions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
